Crucell to Release 2006 Earnings on Tuesday, February 13, 2007
PRESS RELEASE
Crucell to Release 2006 Earnings on Tuesday, February 13, 2007
Leiden, The Netherlands, 31 January 2007 - Dutch biotechnology
company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX)
today announced that it will release its full-year 2006 financial
results on Tuesday, February 13, 2007 at 08:00 Central European Time
(CET) (02:00 US Eastern Daylight Time).
At 14:00 CET, Crucell will conduct a conference call open to all
which will also be webcast. To participate in the conference call,
please call one of the following numbers 10 minutes prior to
commencement:
1-888 495 6452 for the US;
0800 358 5261- for the UK; and
0800 265 85 31 for the Netherlands.
Following a presentation of the results you will be able to ask
questions during a question and answer session.
The live audio webcast can be accessed via the homepage of Crucell's
website at www.crucell.com, and will be archived and available for
replay following the event.
About Crucell
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a
biotechnology company focused on research, development and worldwide
marketing of vaccines and antibodies that prevent and treat
infectious diseases. Its vaccines are sold in public and private
markets worldwide. Crucell's core portfolio includes a vaccine
against hepatitis B, a fully-liquid vaccine against five important
childhood diseases, and a virosome-adjuvanted vaccine against
influenza. Crucell also markets travel vaccines, such as the only
oral anti-typhoid vaccine, an oral cholera vaccine and the only
aluminium-free hepatitis A vaccine on the market. The Company has a
broad development pipeline, with several Crucell products based on
its unique PER.C6® production technology. The Company licenses this
and other technologies to the biopharmaceutical industry. Important
partners and licensees include DSM Biologics, sanofi aventis, GSK and
Merck & Co. Crucell is headquartered in Leiden (the Netherlands),
with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the
US. The Company employs over a 1000 people. For more information,
please visit www.crucell.com.
Forward-looking statements
This press release contains forward-looking statements that involve
inherent risks and uncertainties. We have identified certain
important factors that may cause actual results to differ materially
from those contained in such forward-looking statements. For
information relating to these factors please refer to our Form 20-F,
as filed with the U.S. Securities and Exchange Commission on July 6,
2006, and the section entitled "Risk Factors". The Company prepares
its financial statements under generally accepted accounting
principles in the United States (US GAAP) and Europe (IFRS).
For further information please contact:
Crucell N.V. For Crucell in the US:
Leonard Kruimer Redington, Inc.
Chief Financial Officer Thomas Redington
Tel. +31-(0)71-524 8722 Tel. +1 212-926-1733
Leonard.Kruimer@crucell.com tredington@redingtoninc.com
Barbara Mulder
Tel: 31-(0) 71 524 8718
barbara.mulder@crucell.com
